Pentosan Polysulfate

Progress in retinal and eye research · 2025

Researchers found that prolonged use of pentosan polysulfate (PPS), a medication for bladder pain, is linked to a serious eye condition called PPS maculopathy, which can lead to vision loss. The study highlights the need for greater awareness of this risk as many individuals may be affected without knowing it.

• PPS maculopathy is a progressive eye disorder that can cause central vision loss and impaired dark adaptation.
• There is strong evidence supporting a causal link between PPS use and the development of maculopathy, with risks persisting even after stopping the medication.
• Despite the growing use of PPS, screening for this eye condition remains low, indicating a need for increased awareness and understanding of its potential dangers.

The Canadian journal of urology · 2023

Researchers reviewed the relationship between pentosan polysulfate (PPS), a medication for interstitial cystitis (IC), and pigmentary maculopathy, a vision issue seen in some IC patients. They found no direct evidence linking PPS as the cause of this eye condition, suggesting instead that the underlying inflammation from IC may be responsible.

• There is currently no definitive evidence that pentosan polysulfate causes pigmentary maculopathy.
• Chronic inflammation associated with interstitial cystitis may contribute to the development of pigmentary maculopathy.
• The study proposes that the inflammatory state in IC, rather than PPS use, is the likely factor for the observed eye condition.

Retina (Philadelphia, Pa.) · 2023

Researchers studied the genetic factors associated with maculopathy in patients taking pentosan polysulfate sodium (Elmiron). They found that while no inherited retinal dystrophy genes were linked to the condition, certain genetic variations related to age-related macular degeneration were significantly associated with the maculopathy observed in these patients.

• Researchers identified six genetic variants in five patients, but none confirmed inherited retinal dystrophy.
• Full-field electroretinograms showed nonspecific abnormalities in most patients tested.
• Two specific genetic markers related to age-related macular degeneration were significantly associated with pentosan polysulfate maculopathy.

Pharmaceuticals (Basel, Switzerland) · 2023

Researchers reviewed the potential benefits of pentosan polysulfate (PPS), a molecule with protective properties for various tissues. They found that PPS may help reduce pain and inflammation in conditions like osteoarthritis and promote healing in damaged tissues.

• PPS has been used for decades to alleviate symptoms in conditions like interstitial cystitis and painful bowel disease.
• The molecule can reduce joint pain by removing fatty compounds from blood vessels in osteoarthritis and rheumatoid arthritis.
• PPS stimulates the production of important substances that support tissue health and repair.

Survey of ophthalmology · 2022

Researchers found that long-term use of pentosan polysulfate sodium (PPS), a medication for interstitial cystitis, is linked to a serious eye condition called maculopathy. This condition can threaten vision and may worsen even after stopping the medication. Early symptoms include difficulty seeing in low light and reading, highlighting a significant public health concern.

• There is a strong dose-dependent relationship between PPS use and the development of maculopathy affecting the retina.
• Initial symptoms of maculopathy include prolonged dark adaptation and reading difficulties, while vision may still seem relatively preserved.
• Multimodal retinal imaging is recommended for screening PPS users due to the potential for serious vision loss.

Current opinion in ophthalmology · 2021

Researchers reviewed information on maculopathy, a vision problem linked to pentosan polysulfate sodium (PPS) use. They found that prolonged exposure to PPS can lead to retinal damage, with significant rates of occurrence among long-term users. The study highlights the need for regular eye examinations for those who have used PPS.

• Researchers observed that maculopathy can develop even after stopping PPS, with an average incidence of around 20% in long-term users.
• The study indicated that cumulative dosing of PPS correlates with the likelihood and severity of maculopathy.
• Early estimates suggest that between 12.7% to 41.7% of patients may experience retinal issues based on their PPS exposure.

Handbook of clinical neurology · 2018

Researchers studied the challenges of conducting clinical trials for prion diseases, particularly Creutzfeldt-Jakob disease, which is rare and progresses quickly. They found that traditional trial designs have limitations and suggested that new methods and outcome measures could improve future research efforts.

• Researchers observed that the standard trial design used in other diseases is difficult to implement for Creutzfeldt-Jakob disease due to its rarity and rapid progression.
• The study highlighted that past trials have mainly focused on repurposed drugs and used survival as a primary endpoint, which has its limitations.
• Researchers suggested that incorporating new biomarkers and considering alternative patient populations could enhance future trial designs for prion diseases.

Drugs · 2006

Researchers reviewed the use of pentosan polysulfate, an FDA-approved oral treatment, for relieving bladder pain in adults with interstitial cystitis. They found that it may help repair the protective bladder lining and reduce inflammation, benefiting some patients by improving their overall condition and alleviating pain.

• Pentosan polysulfate is the only FDA-approved oral treatment for bladder pain associated with interstitial cystitis.
• The treatment may help repair the bladder's protective lining and has anti-inflammatory effects.
• Many patients experience improvements in their overall condition and pain relief when using pentosan polysulfate.

Urology · 1997

Researchers found that pentosan polysulfate (Elmiron) is more effective than a placebo in reducing pain, urgency, and frequency of symptoms in patients with interstitial cystitis. However, it did not show a significant difference compared to placebo for nocturia symptoms.

• Pentosan polysulfate was associated with a 16.6% improvement in pain symptoms compared to placebo.
• There was a 13.0% improvement in urgency symptoms with pentosan polysulfate versus placebo.
• No significant difference was observed for nocturia symptoms when comparing pentosan polysulfate to placebo.